VUmc Imaging Center AmsterdamVUmc Imaging Center Amsterdam, comprising Tracer Center Amsterdam

Contact details:

Prof dr Guus van Dongen
De Boelelaan 1117, 1081 HV, Amsterdam
+31 20 4442869

Currently, the imaging infrastructure of VUmc/VU is dispersed over the VUmc/VU campus. Infrastructure comprises: 6 clinical locations Dept Radiology, 5 clinical locations Dept Nuclear Medicine & PET Research, Cyclotron BV for supply of Dutch hospitals with PET tracers, LaserLab voor optische imaging, and the Radionuclide Center for development of new (clinical) PET tracers and their preclinical evaluation in appropriate disease models. In 2013 the Depts Radiology and Nuclear Medicine & PET Research merged, and in 2019 all aforementioned sites will be moved to the new VUmc Imaging Center Amsterdam, of which construction starts in 2016 and will be finished at the begin of 2019. The Radionuclide Center will be named Tracer Center Amsterdam. A main research topic will be “imaging in drug development and application”, which should find solutions for the problem of “expensive” drugs. Expertise ranges from radionuclide production, through new tracer development and preclinical evaluation, to clinical use of new and existing tracers with highly qualified specialists who operate in a truly multidisciplinary environment. The whole process is performed according to state-of-the-art GMP/GLP/GCP standards. In addition, the GMP facilities are inspected on a regular basis by the Dutch Health Care Inspectorate and are licensed to manufacture tracers for human use according to the latest EU guidelines. Moreover, the Imaging Center possesses PET data analysis and training centers.

The VUmc Imaging Center Amsterdam will propel research and public-private interactions in translational high-end molecular imaging and tracer development, an area in which the Netherlands (academia, SMEs as well as large industry) is internationally recognized. Breakthroughs are expected in the form of better understanding of high impact diseases and disease-specific molecular targets, more efficient development and use of diagnostics and (expensive) targeted therapy/drugs, and better understanding of inter-patient variability. These achievements will result in reduced costs of drug development, while bringing better quality of life for patients and a reduction in healthcare costs. The infrastructure will be attractive and have open access for third party users (“on-shoring” of international R&D activities, and creating opportunities for open innovation).
The VUmc Imaging Center Amsterdam (± 15.000 m2) will comprise 3 x 18 MeV cyclotrons and an oxygencyclon for PET radionuclide production and GMP facilities for large scale production of PET tracers that are routinely used in the Dutch clinical.
The Tracer Center Amsterdam (± 2.500 m2) being the R&D environment of the Imaging Center comprises GMP labs with 12 hot cells, 5 research hot cells, 14 fume hoods; extensive facilities for (radio)chemistry, pharmacology, metabolite analysis, biology and animal facilities; preclinical PET/CT, PET/MRI and Optical Scanners; LC-MS/MS and an array of other analytical equipment.
For clinical purposes, the following equipment is available: 1 x PET-MRI (3T): 2 x PET-CT; 1 x SPECT-CT; 1 x Gamma Camera; 3 x CT (64, 128 en 256 MDCT); 4 x MRI (2 x 1,5 T en 2 x 3T);
2 x Angio-intervention units; 7 x Echo-units; 1 X Mammograph; 1 x DXA; 6 x Conventional röntgen unit; several mobile röntgen units for operation theater.

Connection to strategic developments
Life Sciences & Health
Health and Food